Alzheimer’s Disease Clinical trial

Alzheimer’s disease (AD) is at the forefront of modern healthcare concerns for developing countries. AD is a slowly progressive brain disease that can be split into three primary categories; Preclinical AD, Mild Cognitive Impairment (MCI) due to AD and Dementia due to AD. Current treatments for AD are cholinesterase inhibitors or Memantine, which have all been shown to improve the quality of life for the patient when prescribed; however they do not change disease progression or the rate of decline.

The primary aim of this study is to utilise voluntarily provided patient information to improve recruitment in MCI/AD clinical trials which are run by Professor Brew at  St Vincent’s Centre for Applied Medical research; and to engage with current and potential clinical trial participants to develop a recruitment process that caters to the needs of the individual, focusing on streamlining recruitment and reducing trial burden. 

Inclusion Criteria:

• Age 50-85
• Male/Female
• History of memory loss or disturbance confirmed by a doctor

Exclusion Criteria:

• History of Major Head injury
• Contraindications to MRI
• Major Psychiatric disorder
• Uncontrolled Thyroid dysfunction or B12 deficiency

Consent

Informed consent for participation will be obtained by the investigator at their visit. As with all consenting processes, participants will be given the opportunity to review and discuss the study and the consent from with family members prior to their enrolments visit.

Confidentiality

All data generated from the review, will be stored electronically in a re-identifiable format. The data will be securely stored electronically on the SVH server and password protected with access limited to research personnel. 
All data stored will be kept for a maximum of 10 years. No publication is expected to arise form this project.

For more information about this project please email your details to SVHS.NeurologyTrials@svha.org.au